Research Article
Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation
Table 2
Patients’ outcome according to PB-WT1 levels (</≥5 WT1/ABL × 104) evaluated before and after allo-SCT.
| | | PB-WT1/ABL × 104 ≥ 5 | PB-WT1/ABL × 104 < 5 | |
| | Before allo-SCT | | | | | Number of cases | 11 | 13 | | | Number of relapses | 8 (73%) | 4 (31%) | 0.04 | | At 3rd month after allo-SCT | | | | | Number of cases | 9 | 13 | | | Number of relapses | 5 (56%) | 5 (38%) | 0.43 | | At 6th month after allo-SCT | | | | | Number of cases | 7 | 10 | | | Number of relapses | 5 (71%) | 2 (20%) | 0.03 |
|
|
